Market Cap 8.25B
Revenue (ttm) 675.04M
Net Income (ttm) 141.21M
EPS (ttm) N/A
PE Ratio 89.78
Forward PE 84.28
Profit Margin 20.92%
Debt to Equity Ratio 0.00
Volume 209,586
Avg Vol 903,076
Day's Range N/A - N/A
Shares Out 105.19M
Stochastic %K 68%
Beta 0.43
Analysts Strong Sell
Price Target $135.25

Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also develop...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 327 3270
Address:
101 Redwood Shores Parkway, Redwood City, United States
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:09 AM
$CORT is currently trading at $75.75, with an RSI of 56.44 indicating a neutral to slightly bullish momentum. The price is below both the 30-day moving average (MA30) of $77.0 and the 50-day moving average (MA50) of $77.36, suggesting potential resistance at these levels. The 60-day high of $91.0 provides a significant upside target, while the 60-day low of $67.0 establishes a support level. Directional bias leans bullish due to the RSI being above 50, indicating potential for upward movement. Suggested entry point is around $76.00, slightly above the MA30 to confirm momentum. Set a stop-loss at $73.50, just below recent support levels. Target 1 is set at $80.00, near the psychological level and below the MA50. Target 2 is at $85.00, leveraging the gap towards the 60-day high. Monitor for any changes in momentum or market conditions. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:15 AM
$CORT is currently trading at $79.01, with an RSI of 61.68 indicating bullish momentum but nearing overbought territory. The price is above both the 30-day (MA30: 77.52) and 50-day (MA50: 77.09) moving averages, suggesting a positive trend. However, the absence of a 200-day moving average limits long-term trend analysis. Given the 60-day high of $91.00 and low of $67.00, $CORT is currently closer to the high, which may indicate a resistance level around $90.00. The ATR of 3.54 suggests moderate volatility, allowing for reasonable stop placement. Suggested trade plan: - Entry: $79.50 (slightly above current price) - Stop: $76.50 (below MA30 for protection) - Target 1: $85.00 (near resistance) - Target 2: $90.00 (60D high) This plan leverages current bullish indicators while managing risk effectively. https://privateprofiteers.com
0 · Reply
moorenard1
moorenard1 Nov. 12 at 5:53 PM
$CORT SHORT SQUEEZE Shorts SOLD another $65 million of stock in the last two weeks and still were not able to hold the price down. But hey, what's $65 million when you are $1BILLION in the hole. There is no way out for them. Their window to cover is quickly closing. Stock will spike above $150 and get to $200 before they can cover. SHORT SQUEEZE IS INEVITABLE.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:51 AM
$CORT is currently trading at $79.01, with an RSI of 61.68 indicating bullish momentum but nearing overbought territory. The price is above both the 30-day (MA30: 77.52) and 50-day (MA50: 77.09) moving averages, suggesting a positive trend. However, the absence of a 200-day moving average limits long-term trend analysis. Given the 60-day high of $91.00 and low of $67.00, $CORT is currently closer to the high, which may indicate a resistance level around $90.00. The ATR of 3.54 suggests moderate volatility, allowing for reasonable stop placement. Suggested trade plan: - Entry: $79.50 (slightly above current price) - Stop: $76.50 (below MA30 for protection) - Target 1: $85.00 (near resistance) - Target 2: $90.00 (60D high) This plan leverages current bullish indicators while managing risk effectively. https://privateprofiteers.com
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 12 at 1:01 AM
$CORT Share Price: $78.98 Contract Selected: Feb 20, 2026 $80 Calls Buy Zone: $10.20 – $12.60 Target Zone: $18.56 – $22.68 Potential Upside: 72% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
aristocks
aristocks Nov. 11 at 6:12 PM
$CORT about time! Get above 80$ already ;)
0 · Reply
moorenard1
moorenard1 Nov. 11 at 5:08 PM
1 · Reply
michalavis
michalavis Nov. 11 at 1:25 PM
$CORT waiting till end of december - any price fluctuations before that date are irrelevant
0 · Reply
moorenard1
moorenard1 Nov. 10 at 6:29 PM
$CORT Short seller game plan: (1) Dump 200-400k shares right at the open to overwhelm volume, push down stock, and try to scare people into selling. (2) Gradually buy back during day. (3) Dump same 200-400k shares at end of day to try to overwhelm volume and scare people into selling again. (cover in AH) This has become so routine that nobody is falling for their tricks anymore. The problem is, short sellers are 1 billion in the hole. Shorts keep desperately trying to manipulate the stock, but it just isn't working. They were stupid to short the stock in the first place, and are stupid to keep playing these games to try to scare people. They should man up and take their losses and move on, but I honestly think their position is so out of proportion that if they start to cover, stock will instantly shoot up to $200. Anyone who has looked at the company in any serious way understands its worth $150-$200 today, as it sits. SHORT SQUEEZE IS INEVITABLE
1 · Reply
druvaciam
druvaciam Nov. 10 at 2:33 PM
$CORT Everything is green but this stock is -3%, crazy
1 · Reply
Latest News on CORT
Corcept Transition To New Specialty Pharmacy Well Underway

Oct 15, 2025, 9:13 AM EDT - 4 weeks ago

Corcept Transition To New Specialty Pharmacy Well Underway


Corcept Primed For An Upside EPS Surprise

Sep 26, 2025, 12:06 PM EDT - 7 weeks ago

Corcept Primed For An Upside EPS Surprise


PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:09 AM
$CORT is currently trading at $75.75, with an RSI of 56.44 indicating a neutral to slightly bullish momentum. The price is below both the 30-day moving average (MA30) of $77.0 and the 50-day moving average (MA50) of $77.36, suggesting potential resistance at these levels. The 60-day high of $91.0 provides a significant upside target, while the 60-day low of $67.0 establishes a support level. Directional bias leans bullish due to the RSI being above 50, indicating potential for upward movement. Suggested entry point is around $76.00, slightly above the MA30 to confirm momentum. Set a stop-loss at $73.50, just below recent support levels. Target 1 is set at $80.00, near the psychological level and below the MA50. Target 2 is at $85.00, leveraging the gap towards the 60-day high. Monitor for any changes in momentum or market conditions. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:15 AM
$CORT is currently trading at $79.01, with an RSI of 61.68 indicating bullish momentum but nearing overbought territory. The price is above both the 30-day (MA30: 77.52) and 50-day (MA50: 77.09) moving averages, suggesting a positive trend. However, the absence of a 200-day moving average limits long-term trend analysis. Given the 60-day high of $91.00 and low of $67.00, $CORT is currently closer to the high, which may indicate a resistance level around $90.00. The ATR of 3.54 suggests moderate volatility, allowing for reasonable stop placement. Suggested trade plan: - Entry: $79.50 (slightly above current price) - Stop: $76.50 (below MA30 for protection) - Target 1: $85.00 (near resistance) - Target 2: $90.00 (60D high) This plan leverages current bullish indicators while managing risk effectively. https://privateprofiteers.com
0 · Reply
moorenard1
moorenard1 Nov. 12 at 5:53 PM
$CORT SHORT SQUEEZE Shorts SOLD another $65 million of stock in the last two weeks and still were not able to hold the price down. But hey, what's $65 million when you are $1BILLION in the hole. There is no way out for them. Their window to cover is quickly closing. Stock will spike above $150 and get to $200 before they can cover. SHORT SQUEEZE IS INEVITABLE.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:51 AM
$CORT is currently trading at $79.01, with an RSI of 61.68 indicating bullish momentum but nearing overbought territory. The price is above both the 30-day (MA30: 77.52) and 50-day (MA50: 77.09) moving averages, suggesting a positive trend. However, the absence of a 200-day moving average limits long-term trend analysis. Given the 60-day high of $91.00 and low of $67.00, $CORT is currently closer to the high, which may indicate a resistance level around $90.00. The ATR of 3.54 suggests moderate volatility, allowing for reasonable stop placement. Suggested trade plan: - Entry: $79.50 (slightly above current price) - Stop: $76.50 (below MA30 for protection) - Target 1: $85.00 (near resistance) - Target 2: $90.00 (60D high) This plan leverages current bullish indicators while managing risk effectively. https://privateprofiteers.com
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 12 at 1:01 AM
$CORT Share Price: $78.98 Contract Selected: Feb 20, 2026 $80 Calls Buy Zone: $10.20 – $12.60 Target Zone: $18.56 – $22.68 Potential Upside: 72% ROI Time to Expiration: 100 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
aristocks
aristocks Nov. 11 at 6:12 PM
$CORT about time! Get above 80$ already ;)
0 · Reply
moorenard1
moorenard1 Nov. 11 at 5:08 PM
1 · Reply
michalavis
michalavis Nov. 11 at 1:25 PM
$CORT waiting till end of december - any price fluctuations before that date are irrelevant
0 · Reply
moorenard1
moorenard1 Nov. 10 at 6:29 PM
$CORT Short seller game plan: (1) Dump 200-400k shares right at the open to overwhelm volume, push down stock, and try to scare people into selling. (2) Gradually buy back during day. (3) Dump same 200-400k shares at end of day to try to overwhelm volume and scare people into selling again. (cover in AH) This has become so routine that nobody is falling for their tricks anymore. The problem is, short sellers are 1 billion in the hole. Shorts keep desperately trying to manipulate the stock, but it just isn't working. They were stupid to short the stock in the first place, and are stupid to keep playing these games to try to scare people. They should man up and take their losses and move on, but I honestly think their position is so out of proportion that if they start to cover, stock will instantly shoot up to $200. Anyone who has looked at the company in any serious way understands its worth $150-$200 today, as it sits. SHORT SQUEEZE IS INEVITABLE
1 · Reply
druvaciam
druvaciam Nov. 10 at 2:33 PM
$CORT Everything is green but this stock is -3%, crazy
1 · Reply
Jdogg85
Jdogg85 Nov. 10 at 2:29 PM
$CORT 20,000 share insider sell AH friday
0 · Reply
Jdogg85
Jdogg85 Nov. 10 at 2:28 PM
$CORT 65 today lol
1 · Reply
moorenard1
moorenard1 Nov. 8 at 6:51 PM
$CORT To all those short sellers who are telling lies and trying to disparage CORT's oncology program here are two important facts: (1) CORT has not added $7 billion in market cap after the positive cancer results. In mid Feb of 2025 (prior to announcement) it was a $73 stock. Today it is a $73 stock. They literally have $0 of credit in stock for the oncology program. They should have added $10B making it a $170 stock, but alas, shorts have been battering stock relentlessly so we are in the same exact spot we were mid Feb, prior to announcement. Again, zero credit in CORT's stock today for Oncology program. (2) For the knuckleheads comparing CORTs roughly 16 month MoS to Merck's 18 month, Merk's drug is nasty. And when I say nasty, I mean, check out a few of the side-effects:
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Nov. 6 at 8:41 PM
$SLS $CORT Published. Plat Resistant Ovarian Cancer MOS Data today - 15.7 months - saying this 15.7 months of mOS is the new standard of care... Meanwhile GPs + Pembro $MRK Phase 2 Trial achieved a MOS of 18.4 months in a Mostly Platinum REFRACTORY Setting OC Setting. Cort Added 7B in Market Value when it Published this Trial Data - AND GPS is Better. https://igcsmeeting.com/wp-content/uploads/sites/115/2025/11/LBAs-NOV-6.pdf
1 · Reply
aristocks
aristocks Nov. 6 at 6:51 PM
$CORT an additional point I would make and I read this AM, Helathcare is beating technology over past week, 1 month and 3 months (data from finviz) Should help this stock in the long run f the really continues. Do your DD. Not financial advice.
0 · Reply
aristocks
aristocks Nov. 5 at 8:41 PM
$CORT Chart looking great now that earnings are done and dusted: Profit taking 117$ (+53.3%) Stop loss: 67$ (-10.32% I like: 1. Recapture immediately uptrend line; 2. Multiple inflections points (AVWAP+trendline) 3. RSI in the middle 52; 4. MACD at inflection point; 5. 200 EMA acting a stron support 6. Price is now above 20,50 and 200 EMA Limited risk, big reward IMO! Do your DD. This is not financial advice.
0 · Reply
gucag006
gucag006 Nov. 5 at 8:28 PM
$CORT Wow! What's the difference a day brings. What happen to the perma-bears, i.e., shorties, who were singing "sky's falling" here before ER. Seriously, let's talk about the valuation a bit. From Google AI: the Price-to-Sales ratios of pharmaceutical companies are typically between 3 and 5. Let's use the medium # of 4, for $800M in annual sales, CORT's PS ratio is about 10 now - does it is ahead of itself? Absolutely not! With Relacorilant lining up for FDA and EMA approvals for Cushing Syndrome and Platinum-resistant ovarian cancer, the management is project $3B to $5B in annual sales in a couple of years. Just for these two drugs, the MC should be $12B to $20B and the SP should be $120 to $200. Additionally, A) Dazucorilant for ALS, B) Nenocorilant for a broad range of solid tumors, C) Relacorilant for cervical, pancreatic and prostate cancers, D) Miricorilant for MASH. Korlym is like the Old Faithful Geyser spewing out cash regularly! Again, SP $200 by 2026, $300 by 2027.
1 · Reply
ZacksResearch
ZacksResearch Nov. 5 at 5:36 PM
$CORT misses Q3 and slashes outlook — bulls on defense ⚠️ Earnings and revenues both came in below estimates, and even with a 14% year-over-year revenue gain, management cut its 2025 guidance — a tough combo for the stock, now sliding. Full breakdown on what went wrong here 👉 https://www.zacks.com/stock/news/2785792/corcept-q3-earnings-revenues-lag-estimates-25-view-cut-stock-down?cid=sm-stocktwits-2-2785792-teaser-19671&ADID=SYND_STOCKTWITS_TWEET_2_2785792_TEASER_19671
1 · Reply
ZacksResearch
ZacksResearch Nov. 5 at 4:36 PM
$CORT Q3 earnings miss — is the rally losing steam? 📉 Earnings per share fell short at 16 cents vs. the expected 18 cents, and revenue also missed estimates, coming in at $207.6M. The company lowered its 2025 revenue guidance, adding pressure to the stock. Discover the full earnings details here 👉 https://www.zacks.com/stock/news/2785792/corcept-q3-earnings-revenues-lag-estimates-25-view-cut-stock-down?cid=sm-stocktwits-2-2785792-body-19613&ADID=SYND_STOCKTWITS_TWEET_2_2785792_BODY_19613
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Nov. 5 at 3:33 PM
0 · Reply
cheerup1
cheerup1 Nov. 5 at 3:13 PM
$CORT They mentioned in the earnings call that the FDA approval process is proceeding "exactly on the schedule", so we just need to wait.
0 · Reply
aristocks
aristocks Nov. 5 at 2:58 PM
$ZETA while I am happy with the price movement, this should be already above $30 by now.. Good dip buying in $CORT and got more $IREN
0 · Reply